

Determinants of mortality among COVID-19 patients with diabetes mellitus in Addis Ababa, Ethiopia, 2022: An unmatched case-control study

Migbar Sibhat Mekonnen¹, Melsew Getnet Tsegaw², Wuletaw Chane Zewde², Kassie Gebeyehu Tiruneh¹, Asaminew Habtamu Sane³, Taye Mezgebu Ashine⁴, Hailu Asmare Beyene⁵, Melkie Ambaw Mengistie⁶, Edmialeme Getahun Mesfin²

¹Department of nursing, college of health and medical sciences, Dilla University, Dilla, Ethiopia

²Millennium COVID-19 care center, Saint Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia

³School of Nursing, Institute of health sciences, Jimma University, Jimma, Ethiopia

⁴Schools of nursing, college of health science and medicine, Wachamo University, Hosanna, Ethiopia

⁵School of Nursing, College of health science and medicine, Wolaita Sodo University, Sodo, Ethiopia

⁶Department of nursing, Arba Minch College of sciences, Arba Minch, Ethiopia

Correspondence

Migbar Sibhat Mekonnen

Affiliation: Dilla University, Dilla, Ethiopia

Email: bayayibignabez@gmail.com

ORCID: 0000-0002-1240-8551

Keywords: Diabetes mellitus, COVID-19, determinants, risk factors, mortality, Ethiopia

Word count: 3472

References: 51

Abstract

Introduction: COVID-19 remains one of the leading causes of death seeking global public health attention. Diabetes mellitus is associated with severity and lethal outcomes up to death independent of other comorbidities. Nevertheless, information regarding the determinant factors that contributed to the increased mortality among diabetic COVID-19 patients is limited. Thus, this study aimed at identifying the determinants of mortality among COVID-19 infected diabetic patients.

Methods: An unmatched case-control study was conducted on 340 randomly selected patients by reviewing patient records. Data were collected using a structured extraction checklist, entered into Epi data V-4.4.2.2, and analyzed using SPSS V-25. Then, binary logistic regression was used for bivariate and multivariable analysis. Finally, an adjusted odds ratio with 95% CI and a p-value of less than 0.05 was used to determine the strength of association and the presence of a statistical significance consecutively.

Results: The study was conducted on 340 COVID-19 patients (114 case and 226 controls). Patient age (AOR=4.90; 95% CI: 2.13, 11.50), severity of COVID-19 disease (AOR=4.95; 95% CI: 2.20, 11.30), obesity (AOR=7.78; 95% CI: 4.05, 14.90), hypertension (AOR=5.01; 95% CI: 2.40, 10.60), anemia at presentation (AOR=2.93; 95% CI: 1.29, 6.65), and AKI after hospital admission (AOR=2.80; 95% CI: 1.39, 5.64) had statistically significant association with increased mortality of diabetic patients with COVID-19 infection. Conversely, presence of RVI co-infection was found to be protective against mortality (AOR=0.35; 95% CI: 0.13, 0.90).

Conclusion: Patient age (<65years), COVID-19 disease severity (mild and moderate illness), presence of hypertension, obesity, anemia at admission, and AKI on admission was independently associated with increased mortality of diabetic COVID-19 patients. Contrariwise, the presence of RVI co-infection was found to be protective against patient death. Consequently, COVID-19 patients with diabetes demand untiring efforts, and focused management of the identified factors will substantially worth the survival of diabetic patients infected with COVID-19.

What is already known on this topic?

Diabetes mellitus is associated with severity and lethal outcomes up to death independent of other comorbidities. Previous studies indicated that diabetic patients have almost four times increased risk of severe disease and death due to COVID-19 infection. Consequently, with this increased mortality and other public health impacts, numerous reports have been evolved worldwide on the link between COVID-19 and DM, and diabetes management during the COVID-19 pandemic. However, information regarding the determinant factors that lead to the increased mortality among diabetic COVID-19 patients is not well-studied yet.

What this study adds?

- Patient age (<65years), COVID-19 disease severity (mild and moderate illness), presence of hypertension, obesity, anemia at admission, and AKI on hospital admission were independently associated with increased mortality of COVID-19 patients with DM.
- In addition, RVI co-infection was found to be protective against patient death.

Introduction

The coronavirus disease 2019 (COVID-19) pandemic, which is caused by a highly pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in millions of morbidities and mortalities worldwide (1-3). COVID-19 has drawn drastic attention and poses a healthcare threat globally. The devastating effects of the COVID-19 pandemic were highly associated with chronic medical conditions, mainly diabetes mellitus (DM). The estimated global prevalence of diabetes in 2021 was 10.5% (537 million), a 16% (74 million) rise since 2019. The international diabetes federation (IDF) projected that the number of diabetic patients will increase to 11.3% (643 million) by 2030 and 12.2% (783 million) by 2045 (4). The prevalence of diabetes among COVID-19 patients has been estimated up to 31% (5).

Diabetes mellitus (DM) is one of the most frequent comorbidities that occurred in patients with coronavirus disease 2019 (COVID-19) and is associated with severity and lethal outcomes such as intensive care unit (ICU) admission, invasive ventilation, and death (6-8) independent of other comorbidities. Furthermore, the presence of typical complications of diabetes mellitus (cardiovascular disease, heart failure, and chronic kidney disease) increases COVID-19 mortality (6, 9-11). It has been observed that 1.5% of in-hospital deaths related to COVID-19 occurred in patients with type 1 DM and 31.4% in patients with type 2 DM (9).

Deaths in people with diabetes have more than doubled during the COVID-19 epidemic (9). Another study indicates that diabetic patients have almost four times the risk of severe disease and death from COVID-19 (12). The presence of DM is frequently associated with worse outcomes even among patients presented with mild or no COVID-19 symptoms (13).

Consequently, with this increased mortality and other public health impacts, numerous reports have been evolved worldwide on the link between COVID-19 and DM, and diabetes management during the COVID-19 pandemic (14). Predicting worse patient outcomes using poor glycemic control is not an innovation. For instance, fasting blood sugar level was identified as an independent predictor of severity during the 2009 H1N1 influenza pandemic (15). Due to the deregulation of the immune system, diabetic patients are highly vulnerable to infectious diseases. Irrespective of the previous history of DM, hyperglycemia leads to impaired immune function and increased susceptibility to infections, and has been associated with an increased patient death (16, 17).

With the high prevalence of diabetes and its devastating public health consequences, it is demanding to understand the unique aspects of COVID-19 infection in people with diabetes. To control the pandemic, it can be even more significant these days and in the future due to the changes in the lifestyle and healthcare service delivery system. Furthermore, recent studies indicated the need for special considerations in diabetes management among COVID-19 patients (18). Besides, people with diabetes are more concerned about becoming infected with COVID-19 than people without diabetes (19). Thus, this study aimed at identifying the determinants of mortality among COVID-19 infected diabetic patients.

Methods

An unmatched case-control study was employed by reviewing charts of patients admitted to Addis Ababa COVID-19 care centers from September 2020 to August 2021. Addis Ababa, the capital city of Ethiopia, has three main COVID-19 treatment centers. Millennium COVID-19 care center is the largest and best equipped of all those centers, with a capacity of 1040 patient beds and more than 40 intensive care unit beds. The source population was all COVID-19 patients who died in the center. Patients who died during the specified period were considered the study population. Cases were COVID-19 diagnosed DM patients who died while admitted to the center, whereas controls were COVID-19 patients without a diagnosis of DM and who died in the COVID-19 care center. Medical records without

HgA1c and patients with stress hyperglycemia without elevated HgA1c were excluded from the study.

Sample size and recruitment methods

The sample size was estimated using the double population proportion formula by the statcalc program of Epi info software, considering unmatched case-control study assumptions. The parameters used include 95% confidence level, 80% study power, control to case ratio of two, percentage of controls exposed=60%, and an odds ratio of 2.04 (20) that yields 341. Afterward, 114 cases (diabetic patients) and 228 controls (non-diabetic patients) were incorporated. Cases were selected consecutively, and two respective controls next to the sampled case were included randomly with replacement after confining all death records in their order of medical record number (MRN).

Data collection tools, procedures, and quality control

Initially, the lists of one-year death records were sorted out. Among those, medical records of diabetic and non-diabetic patients were further confined separately using a computer-generated system and arranged orderly using their medical record number (MRN). Afterward, data collection was conducted using a pretested and structured extraction checklist from medical records of COVID-19 patients who were died in the treatment center. A one-year data (patient records from September 2020 to August 2021) was used to conduct the study. The extraction checklist comprised socio-demographic characteristics, disease severity, comorbidities, baseline vital signs, and laboratory findings, as well as COVID-19 management and complication-related questions. Four data collectors and two supervisors were recruited and trained for half-day about the data collection requirements. The completeness of the collected data was cross-checked daily.

Statistical analysis and data presentation

After completion of data collection, data were coded and entered into Epi data manager version 4.4.2.2. Then, it was exported to SPSS software version 25 for analysis. Crosstabulation and explorative analysis was done for data cleaning and to determine the data distribution. Categorical data were described using frequency and percent, and mean with standard deviation (SD) or median with interquartile range (IQR) were applied to describe continuous data based on data distribution. Afterward, bivariate and multivariable analyses were run using the binary logistic regression model. After bivariate analysis, a p-value of 0.25 or less was considered to recruit candidate variables for the multivariate model. The model fitness test was checked using Hosmer and Lemeshow test ($p=0.302$). Finally, an

adjusted odds ratio with a 95% confidence interval was used to report the strength of association, and statistical significance was declared at a p-value of less than 0.05.

Patient and public involvement

It is not applicable for this study since patients were not directly involved. The study was conducted via patient chart review without contacting patients.

Ethical consideration

Ethical clearance was obtained from Saint Paul's Millennium Medical College institutional review board (IRB). The IRB waived such that the study can be conducted via patient chart review. Then, the chief executive director and the clinical director were communicated about the purpose of the study, and permission was obtained on behalf of patients to access the data. The study was conducted based on the declaration of Helsinki. Anonymity and confidentiality were attained via coding and aggregate reporting, with no individual patient identifiers collected in the extraction process.

Results

Socio-demographic characteristics

This case-control study was conducted on 114 cases (diabetic patients) and 226 controls (non-diabetic patients) that were died due to COVID-19 diseases. About 37.6% of the study subjects were female, of which 27.3% were diabetics. The mean age was 65 years (SD=13.18) among cases and 68.7 years (SD=13.5) among controls ranging from 30 to 94 years. Half of the cases were above the age of 65years, and it was above 62 years among the controls (Table 1).

Table 1: Distribution of socio-demographic characteristics among patients who died due to COVID-19 in Addis Ababa, Ethiopia, 2022 (n=340)

Variables	Category	Outcome variable			P-value
		DM (%)	No DM (%)	Total (%)	
Sex	Male	79 (69.3)	133 (60.6)	212 (62.4)	0.060
	Female	35 (30.7)	93 (39.4)	128 (37.6)	
Age (years)	30-40	9 (7.9)	9 (4)	18 (5.3)	0.003
	41-50	6 (5.3)	18 (8)	24 (7.1)	
	51-60	23 (20.2)	21 (9.3)	44 (12.9)	

61-70	41 (36)	84 (37.2)	125 (36.8)
71-80	9 (7.9)	48 (21.2)	57 (16.8)
≥81	26 (22.8)	46 (20.3)	72 (21.2)

COVID-19 severity, comorbidity, and presenting symptoms among patients who died due to COVID-19 patients

The median time from the onset of COVID-19 symptoms to hospital admission was five days (IQR=6) among the cases and seven days (IQR=5) among controls. The study finding also showed that 298 (86.6%) patients were admitted with severe or critical COVID-19 illness, of which 39.3% had diabetes mellitus. The proportion of death among patients admitted with mild and moderate COVID-19 illness was five-fold among the cases (25.4%) compared to non-diabetic patients (5.8%). One-hundred and thirty-seven (40.3%) who died of COVID-19 infection were obese; of those, 58.4% had diabetes mellitus. On the other hand, 82.1% of study participants had comorbid conditions. Hypertension (52.3%), RVI (20.4%), and cardiac illnesses (17.6%) were the commonest comorbidities. Almost two-thirds of the cases (diabetic patients) that died-off COVID-19 diseases were hypertensive, whereas one-third of the controls (non-diabetics) had hypertension. Regarding the presenting COVID-19 symptoms, cough (92.6%) and dyspnea (79.4%) were the frequently reported complaints, followed by easy fatigability (44.4%), myalgia (32.9%), anorexia (16.2%), and chest pain (11.8%) (Table 2).

Table 2: COVID-19 severity, comorbidity, and COVID-19 symptoms among patients who died from COVID-19 infection in Addis Ababa, Ethiopia, 2022 (n=340)

Variable	Category	Outcome variable			P-value
		DM (%)	No DM (%)	Total (%)	
COVID-19 Severity	Mild	5 (4.4)	1 (0.4)	6 (1.8)	<0.001
	Moderate	24 (21.1)	12 (5.3)	36 (10.6)	
	Severe/critical	85 (74.5)	213 (94.3)	298 (87.6)	
Obesity	No	34 (29.8)	169 (74.8)	203 (59.7)	<0.001
	Yes	80 (70.2)	57 (25.2)	137 (40.3)	
Comorbidities	No	15 (13.2)	46 (20.4)	61 (17.9)	0.103
	Yes	99 (86.8)	180 (79.6)	279 (82.1)	
HTN	No	46 (40.4)	148 (65.5)	194 (57.1)	<0.001
	Yes	68 (59.6)	78 (34.5)	146 (42.9)	
Cardiac	No	92 (80.7)	199 (88.1)	291 (85.6)	0.068

	Yes	22 (19.3)	27 (11.9)	49 (14.4)	
Stroke	No	106 (93)	208 (92)	314 (92.4)	0.756
	Yes	8 (7)	18 (8)	26 (7.6)	
CKD	No	111 (97.4)	220 (97.3)	331 (97.4)	0.990
	Yes	3 (2.6)	6 (2.7)	9 (2.6)	
RVI	No	105 (92.1)	178 (78.8)	283 (83.2)	0.002
	Yes	9 (7.9)	48 (21.2)	57 (16.8)	
Cancer	No	111 (97.4)	224 (99.1)	335 (98.5)	0.318
	Yes	3 (2.6)	2 (0.9)	5 (1.5)	
Presenting symptoms	Anorexia	3 (2.6)	52 (23)	55 (16.2)	<0.001
	Fatigue	42 (36.8)	109 (48.2)	151 (44.4)	0.046
	Headache	9 (7.9)	27 (11.9)	36 (10.6)	0.252
	Fever	8 (7)	45 (19.9)	53 (15.6)	0.002
	Cough	108 (94.7)	207 (91.6)	315 (92.6)	0.294
	Dyspnea	95 (83.3)	175 (77.4)	270 (79.4)	0.204
	Sore throat	3 (2.6)	18 (8)	21 (6.2)	0.054
	Myalgia	34 (29.8)	78 (34.5)	112 (32.9)	0.385
	Chest pain	16 (14)	24 (10.6)	40 (11.8)	0.356

Key: DM: diabetes mellitus, COVID-19: coronavirus disease 2019, HTN: hypertension, CKD: chronic kidney disease, RVI: retroviral infection

Baseline vital signs and laboratory investigations

According to the study results, 36% of the cases and 13.3% of the controls had systolic blood pressure above 140mmHg. Additionally, the proportion of tachycardia and tachypnea was comparable among the cases (51% and 73.7%) and the controls (53.5% and 78.7%) respectively. Likewise, 23.2% and 23.8% of the patients were anemic (Hgb<12mg/dl) and thrombocytopenic (Plt<150) in that order. The average WBC count was 11.14 (SD=5.34) among diabetic patients and 13.65 (SD=5.7) among patients without DM. The mean HgA1c among DM patients was 7.1% (SD=1.80), whereas it was 5.34 (SD=0.99) among non-diabetics. Moreover, 57.4% of the patients had random blood sugar (RBS) level of 200mg/dl at baseline, with a comparable proportion among cases and controls. About 17.5% of the cases and 13.3% of the controls had hyperkalemia ($K^+ > 5.2$ mmol/L) at admission. At the time of hospital admission, the cases had a serum albumin level of 2.70 (IQR=1.19), and it was 2.19 (IQR=1.14) among controls. Hypoalbuminemia (<3.4g/dl) was recorded among 76.3% of the cases and 78.8% of the controls on admission.

Table 3: Distribution of baseline vital signs and laboratory investigations among patients who died due to COVID-19 in Addis Ababa, Ethiopia, 2022 (n=340)

Parameter	Category	Outcome variable			P-value
		DM (%)	No DM (%)	Total (%)	
SBP (mmHg)	<90	3 (2.6)	33 (14.6)	36 (10.6)	<0.001
	90-139	70 (61.4)	163 (72.1)	233 (68.5)	
	≥140	41 (36)	30 (13.3)	71 (20.9)	
DBP (mmHg)	<60	20 (17.5)	36 (15.9)	56 (16.5)	<0.001
	60-89	60 (52.6)	162 (71.7)	222 (65.3)	
	≥90	34 (29.8)	28 (12.4)	62 (18.2)	
Pulse rate (beats/minute)	<60	6 (5.3)	21 (9.3)	27 (7.9)	0.285
	60-99	50 (43.9)	84 (37.2)	134 (39.4)	
	≥100	58 (50.9)	121 (53.5)	179 (52.6)	
Respiratory rate (breaths/minute)	10-24	30 (26.3)	48 (21.2)	78 (22.9)	0.293
	>24	84 (73.7)	178 (78.8)	262 (77.1)	
SPO2	<90%	75 (65.8)	124 (54.9)	199 (58.5)	0.054
	≥90%	39 (34.2)	102 (45.1)	141 (41.5)	
WBC (cells×10 ³ per microliter)	<4.5	16 (14)	6 (2.7)	22 (6.5)	<0.001
	4.5-11.0	38 (33.3)	96 (42.5)	134 (39.4)	
	>11.0	60 (59.6)	124 (54.9)	184 (54.1)	
Hemoglobin	<12g/dl	34 (29.8)	45 (19.9)	79 (23.2)	0.041
	≥12g/dl	80 (70.2)	181 (80.1)	261 (76.8)	
Platelet (cells per microliter)	<150×10 ³	35 (30.7)	46 (20.4)	81 (23.8)	0.034
	≥150×10 ³	79 (69.3)	180 (79.6)	259 (76.2)	
Creatinine	≤1.2mg/dl	86 (75.4)	184 (81.4)	270 (79.4)	0.198
	>1.2mg/dl	28 (24.6)	42 (18.6)	70 (20.6)	
Potassium (mmol/L)	<3.5	3 (2.6)	9 (4)	12 (3.5)	0.494
	3.5-5.2	91 (79.8)	187 (82.7)	278 (81.8)	
	>5.2	20 (17.5)	30 (13.3)	50 (14.7)	
Albumin	<3.4g/dl	87 (76.3)	178 (78.8)	265 (77.9)	0.608
	≥3.4g/dl	27 (23.7)	48 (21.2)	75 (22.1)	
RBS	<200mg/dl	49 (43)	96 (42.5)	145 (42.6)	0.929
	≥200mg/dl	65 (57)	130 (57.5)	195 (57.4)	

Key: DM: diabetes mellitus, SBP: systolic blood pressure, DBP: diastolic blood pressure, SPO2: peripheral oxygen saturation, WBC: white blood cell, ALT: alanine transaminase, RBS: random blood sugar

Description of management-related variables and complications

The median time from hospital admission to death was ten days (IQR=7) among the cases (diabetic patients) and eight days (IQR=8) among controls (patients without DM). The study findings notified that 95.6% of the study participants received either non-invasive or invasive mechanical ventilator support. Two-thirds (66.7%) of the patients who were supported with nasal prong or face mask were diabetics, and only one-third (33.3%) were without diabetes. All patients took antibiotics, thromboprophylaxis, and corticosteroid therapy. Besides, 48.2%, 21.1%, 17.5%, and 11.4% of the cases received antihypertensive medications, diuretics, cholesterol-lowering drugs, and antivirals such as remdesivir respectively. Concerning the COVID-19 related complications, 49.1% of the cases developed AKI, which is true among 38.9% of the controls.

Table 4: Tabulation of management-related variables and COVID-19 complications among patients who died due to COVID-19 in Addis Ababa, Ethiopia, 2022 (n=340)

Parameter	Category	Outcome variable			P-value
		DM (%)	No DM (%)	Total (%)	
Method of ventilation	NP or FM	10 (8.8)	5 (2.2)	15 (4.4)	<0.001
	NIPPV	44 (38.6)	56 (24.8)	100 (29.4)	
	IV	60 (52.6)	165 (73)	225 (66.2)	
Diuretics	No	90 (78.9)	194 (85.8)	284 (83.5)	0.106
	Yes	24 (21.1)	32 (14.2)	56 (16.5)	
Antihypertensive administered	No	59 (51.8)	163 (72.1)	222 (65.3)	>0.001
	Yes	55 (48.2)	63 (27.9)	118 (34.7)	
Statins use	No	94 (82.5)	191 (84.5)	285 (83.8)	0.627
	Yes	20 (17.5)	35 (15.5)	55 (16.2)	
Antivirals (remdesivir)	No	101 (88.6)	209 (92.5)	310 (91.2)	0.234
	Yes	13 (11.4)	17 (7.5)	30 (8.8)	
Prone	No	37 (32.5)	48 (21.2)	85 (25)	0.024
	Yes	77 (67.5)	178 (78.8)	255 (75)	
HAI/VAP	No	37 (32.5)	61 (27)	98 (28.8)	0.294
	Yes	77 (67.5)	165 (73)	242 (71.2)	
ICU delirium	No	101 (88.6)	211 (93.4)	312 (91.8)	0.131
	Yes	13 (11.4)	15 (6.6)	28 (8.2)	
Coagulopathy	No	90 (78.9)	175 (77.4)	265 (77.9)	0.751
	Yes	24 (21.1)	51 (22.6)	75 (22.1)	
AKI	No	58 (50.9)	138 (61.1)	196 (57.6)	0.073
	Yes	56 (49.1)	88 (38.9)	144 (42.4)	
Shock	No	51 (44.7)	99 (43.8)	150 (44.1)	0.870

	Yes	63 (55.3)	127 (56.2)	190 (55.9)	
ALI	No	81 (71.1)	165 (73)	246 (72.4)	0.703
	Yes	33 (28.9)	61 (27)	94 (27.6)	
Length of hospital stay (days)	<7	33 (29)	75 (33.2)	108 (31.8)	0.696
	7-14	60 (52.6)	109 (48.2)	169 (57.6)	
	>14	21 (18.4)	42 (18.6)	63 (18.5)	

Key: DM: diabetes mellitus, NP: nasal prong, FM: face mask, NIPPV: non-invasive positive pressure ventilation, IV: invasive ventilation, ART: antiretroviral therapy, ARDS: acute respiratory distress syndrome, HAI: hospital-acquired infection, VAP: ventilator-associated pneumonia, ICU: intensive care unit, AKI: acute kidney injury, ALI: acute liver injury

Determinants of mortality among COVID-19 patients with diabetes mellitus

After data description, inferential analysis was conducted using the binary logistic regression model. Bivariate analysis was done to determine the association of each explanatory variable to the outcome variable. Then, the multi-collinearity check was done, and some variables such as antihypertensive use and pulse rate at baseline were excluded since they have a variance inflation factor (VIF) score of greater than ten. Then, variables that fulfilled the test assumptions and had a p-value of less than 0.25 in the bivariate analysis were candidates for the final model. After checking the model fitness test, a multivariate analysis was run by incorporating the candidate variables. Finally, having obesity, hypertension, retroviral infection, anemia at admission, AKI after hospital admission, COVID-19 severity, and patients' age were found to have a statistically significant association with mortality of diabetic and COVID-19 infected patients.

Table 5: Binary logistic regression output for the determinant factors of mortality among diabetic COVID-19 patients in Addis Ababa, Ethiopia, 2022 (n=340)

Covariates	Category	Outcome		Crude OR (95% CI)	Adjusted OR (95% CI)	Sig.
		DM	No DM			
Gender	Male	79	133	1.58 (0.98, 2.55)	1.34 (0.64, 2.79)	0.443
	Female	35	93	Reference	Reference	
Age in years	<65	49	72	1.61 (1.03, 2.60)	4.90 (2.13, 11.50)	<0.001*
	≥65	65	154	Reference	Reference	
COVID-19 severity	Mild or moderate	30	39	1.71 (0.99, 2.95)	4.95 (2.20, 11.30)	<0.001*
	Severe	84	187	Reference	Reference	
Obesity	No	34	169	Reference	Reference	
	Yes	80	57	6.98 (4.20, 11.5)	7.78 (4.05, 14.90)	<0.001*
HTN	No	46	148	Reference	Reference	
	Yes	68	78	2.8 (1.80, 4.50)	5.01 (2.40, 10.60)	<0.001*
Cardiac	No	92	199	Reference	Reference	

illnesses	Yes	22	27	1.76 (0.95, 3.26)	1.92 (0.77, 4.80)	0.162
RVI	No	105	178	Reference	Reference	
	Yes	9	48	0.32 (0.15, 0.67)	0.35 (0.13, 0.90)	0.030*
Fever	No	8	45	Reference	Reference	
	Yes	106	181	0.30 (0.14, 0.67)	0.44 (0.15, 1.27)	0.128
SPO2	<90%	75	124	1.6 (0.99, 2.50)	1.14 (0.58, 2.25)	0.693
	≥90%	39	102	Reference	Reference	
WBC (cells/μL)	≤11×10 ³	54	102	Reference	Reference	
	>11×10 ³	60	124	0.91 (0.58, 1.40)	1.10 (0.58, 2.12)	0.767
Hemoglobin	<12g/dl	34	45	1.71 (1.02,2.9)	2.93 (1.29, 6.65)	0.010*
	≥12g/dl	80	181	Reference	Reference	
Platelet (cells/μL)	<150×10 ³	35	46	1.73 (1.04,2.9)	0.85 (0.34, 2.02)	0.710
	≥150×10 ³	79	180	Reference	Reference	
Urea	<60mg/dl	79	184	Reference	Reference	
	≥60mg/dl	35	42	1.94 (1.20,3.30)	1.15 (0.51, 2.50)	0.774
Proning	No	37	48	Reference	Reference	
	Yes	77	178	0.56 (0.34, 0.93)	0.63(0.29, 1.34)	0.252
Diuretics use	No	90	194	Reference	Reference	
	Yes	24	32	1.60 (0.90, 2.90)	2.2(0.96, 4.96)	0.064
Antiviral use	No	101	209	Reference	Reference	
	Yes	13	17	1.59 (0.74, 3.39)	3.5 (0.94, 10.13)	0.052
Method of ventilation	NP or FM	10	5	Reference	Reference	
	NIPPV	44	56	0.39 (0.13, 1.23)	0.69 (0.13, 3.65)	0.669
	IV	60	165	0.18 (0.06,0.55)	0.46 (0.10, 2.25)	0.338
AKI	No	58	138	Reference	Reference	
	Yes	56	88	1.5 (0.96, 2.39)	2.80 (1.39, 5.64)	0.004*
ICU delirium	No	101	211	Reference	Reference	
	Yes	13	15	1.80 (0.83, 3.95)	2.01 (0.59, 6.88)	0.266

Note: *statistically significant at 95% confidence level

Key: DM: diabetes mellitus, HTN: hypertension, RVI: retroviral infection, SPO2: peripheral oxygen saturation, WBC: white blood cell, NP: nasal prong, FM: face mask, NIPPV: non-invasive positive pressure ventilation, IV: invasive ventilation, AKI: acute kidney injury, ICU: intensive care unit

Discussion

COVID-19 disease remains one of the leading causes of death seeking public health attention. The mortality rate is even higher among diabetic patients (21). Several studies conducted in the COVID-19 era also reported a strong association between DM and COVID-19 mortality. Nevertheless, information regarding the determinants factors that lead to the increased mortality among diabetic COVID-19 patients is limited. Thus, this study aimed at identifying the determinants of mortality among COVID-19 infected diabetic patients.

The odds of death among diabetic patients under 65 years of age were almost five-fold [(AOR=4.90; 95% CI: 2.13, 11.50), p=<0.001] higher than non-diabetic patients in the same age group did. Previous studies showed the association of COVID-19 patients with advanced

age (>65 years). This finding is evidenced in the general population (diabetic and non-diabetic patients) (22, 23). Conversely, the current study reported that patients younger than 65 years are also at a higher risk of death than those without DM. This association might be rationalized by the immune suppression frequently noted in patients with DM than in the general population. This finding implies the need for similar concerns for all diabetic COVID-19 patients irrespective of age strata.

The study finding also revealed that diabetic patients who were admitted with mild and moderate COVID-19 disease had five times [(AOR=4.95; 95% CI: 2.20, 11.30), $p<0.001$] increased chance of mortality compared with non-diabetic patients with the same disease severity. Even though not specific to patients with DM, existing evidence documented high mortality among patients who presented with severe COVID-19 illness (23). Equally, the current study notified that having DM would raise the risk of mortality even among those admitted with mild and moderate COVID-19 illness. The scientific reason might be that SARS-COV-2 infection may worsen the disease for people with diabetes by suppressing β -cell function and exacerbating acute metabolic complications (24). The other possible justification could be the weak host immune defense evidenced among diabetic patients that is incapable to halt the viral replication and progress of infection. Consequently, mild and moderate illnesses can be frequently progressed to severe disease among patients with DM than in those who have no DM.

Furthermore, obese patients ($BMI \geq 30$) were 7.78 times more likely to die compared to their counterparts [(AOR=7.78; 95% CI: 4.05, 14.90), $p<0.001$]. Earlier studies conducted on risk factors of mortality among COVID-19 patients supported this finding (7, 9, 25, 26). The pathologic link between mortality of diabetes COVID-19 patients and obesity can be multifactorial. First, obesity can make oxygenation and ventilation more difficult by compromising lung capacity and reserve (27). It is also documented that obesity is associated with impaired immune function (28, 29).

Likewise, the odds of death were five times higher among diabetic patients with hypertension comorbidity than those without hypertension [(AOR= 5.01; 95% CI: 2.40, 10.60), $p<0.001$]. Former studies conducted in China and Nigeria also showed the association of hypertension with increased mortality of COVID-19 patients (30-33). The exact pathologic link between hypertension and COVID-19 is unclear yet. Nevertheless, the literature hypothesized a higher affinity of SARS-COV-2 to the angiotensin-converting-enzyme receptor-2 (ACE2), which will accelerate viral binding to the epithelial cells of vital organs such as the lung and cardiac

(34, 35), resulting in cytokine accumulation in these organs. This increased cytokine concentration (cytokine storm) can lead to acute lung injury, ARDS, and multiple organ failure (36). Besides, cytokine storm is highly linked with the progression of hypertension (37) which could result in severe inflammatory responses and complications.

Diabetic patients who had anemia at presentation (Hgb<12g/dl) were at advanced risk of mortality compared to those with normal hemoglobin levels [(AOR=2.93; 95% CI: 1.29, 6.65), p=0.010]. A prospective study conducted on 1257 Iranian COVID-19 patients reported similar findings (38). However, studies conducted in China (39) and Italy (40) did not confine with the current study results. The possible reason might be that patients with decreased hemoglobin levels have reduced oxygen-carrying capacity that can precipitate type-1 respiratory failure. Moreover, anemia is associated with sympathetic nervous system activation. That, in turn, escalates the metabolic demand and pulmonary capillary leakage, ending up with ARDS (41). Anemia may also further suppress the already compromised immune defense of diabetic patients; and thus, lead to an increased chance of mortality among COVID-19 patients.

Moreover, the risk of mortality of diabetic patients who developed AKI was 2.80 times higher than their counterparts [(AOR=2.80; 95% CI: 1.39, 5.64), p=0.004]. This finding is supported by the results of earlier studies conducted in the USA(42), Korea (43), France (44), and a meta-analysis (45). This scientific link may be explained by the pathophysiologic mechanism of COVID-19 disease itself. The SARS-COV-2 may enter the ACE2 receptor (ACE2 is highly prevalent in the kidney) and cause direct injury to the kidney, increased pro-inflammatory viral cytokines, and thrombotic events. On the other hand, AKI is highly prevalent in critical patients with hemodynamic instabilities, severe ARDS (requiring high PEEP levels of ventilation), decreased cardiac output, hypervolemia, sepsis, and those who received nephrotoxic drugs (44). All those conditions are associated with more severe illness and higher mortality. Conversely, poorly controlled diabetes mellitus is also associated with kidney injury (nephropathy), which will worsen patient outcomes.

Unexpectedly, patients who had RVI co-infection were 65% [(AOR=0.35; 95% CI: 0.13, 0.90), p=0.030] less likely to die-off COVID-19 disease compared to those without RVI co-infection. Contradicting results were documented regarding the effect of HIV status and COVID-19 mortality. Some studies showed a statistically significant association between RVI on increased mortality of COVID-19 patients (46). On the contrary, several studies declared that no significant association exists between these variables (47-49). All RVI

patients in this cohort were on HAART. Most of the ART regimens were hypothesized to have a therapeutic effect on COVID-19 infection (50), and some (such as remdesivir) were partially recommended as supportive management modalities for patients with COVID-19 disease (51). Even though remdesivir and other ART drugs are no more recommended for COVID-19 patients by WHO, they were still under investigation in clinical trials and in use by some clinical set-ups. Hence, this might be the possible reason for a better outcome. The variation in the effect and COVID-19 outcome among RVI patients could be due to the variation in the management guideline.

This study has certain limitations. First, it would be nice to run a stratified analysis for each type of DM and differentiate among newly versus known diabetic patients, which is not the case in our study. It did not enable us to see the possible variation in the mortality and factors affecting it among the two groups (newly diagnosed and chronic DM). Second, the retrospective nature of the study would delimit the strength of evidence drawn from the study since data were not collected primarily for research purposes.

Conclusion

This case-control study identified pertinent factors including socio-demographic, disease severity, comorbidities, and complications of COVID-19 that can determine the mortality among COVID-19 infected diabetic patients. Patient age (<65years), COVID-19 disease severity (mild and moderate illness), presence of hypertension, obesity, anemia at admission, and AKI on hospital admission was independently associated with increased mortality of COVID-19 patients with DM. In addition, RVI co-infection was found to be protective against patient death. Consequently, COVID-19 patients with DM require untiring efforts irrespective of age specification and disease severity at admission. Besides, focused management of hypertension and other identified factors will significantly worth the survival of diabetic patients infected with COVID-19.

Abbreviations: AKI: acute kidney injury, ALI: acute liver injury, ALT: alanine transaminase, ARDS: acute respiratory distress syndrome, CKD: chronic kidney disease, DBP: diastolic blood pressure, DM: diabetes mellitus, FM: face mask, HAART: highly active antiretroviral therapy, HAI: hospital-acquired infection, HTN: hypertension, ICU: intensive care unit, IV: invasive ventilation, NIPPV: non-invasive positive pressure ventilation, NP: nasal prong, RBS: random blood sugar, RVI: retroviral infection, SBP: systolic blood

pressure, SPO2: peripheral oxygen saturation, VAP: ventilator-associated pneumonia, WBC: white blood cell.

Acknowledgments: The authors acknowledged the hospital administrators, data collectors, supervisors, and record officers.

Funding: This research received no specific grant from any funding agency.

Authors' contributions: MSM generated the concept and developed the proposal. MGT, MSM, & WCZ designed the study and developed the data extraction tool. KGT, TMA, AHS, MAM, EGM, WCZ & HAB participated in data collection and supervision. MSM performed the statistical analysis and drafted the manuscript. MGT, MSM, AHS & TMA edited and formatted the manuscript for publication. All the authors read, critically revised, and approved the final version of the manuscript. Finally, all the contributors agreed to be equally accountable for every aspect of the work.

Disclosure: No conflicts of interest to be disclosed.

Data sharing statement: The data owner of this study is the millennium COVID-19 care center. Thus, extra data that support the findings of this study are available from the corresponding author upon reasonable request and can be shared upon legal request.

Consent for publication: Not applicable

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. *New England journal of medicine*. 2020.
2. World Health Organization. Coronavirus disease (COVID-19) pandemic. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>. 2022.
3. Ugwueze CV, Ezeokpo BC, Nnolim BI, Agim EA, Anikpo NC, Onyekachi KE. COVID-19 and Diabetes Mellitus: The Link and Clinical Implications. *Dubai Diabetes and Endocrinology Journal*. 2020;26(2):69-77.
4. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes research and clinical practice*. 2022 2022/01/01/;183:109119.
5. Bradley SA, Banach M, Alvarado N, Smokovski I, Bhaskar SM. Prevalence and impact of diabetes in hospitalized COVID-19 patients: A systematic review and meta-analysis. *Journal of diabetes*. 2022;14(2):144-57.

6. Shi Q, Zhang X, Jiang F, Zhang X, Hu N, Bimu C, et al. Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center, retrospective study. *Diabetes care*. 2020;43(7):1382-91.
7. Kompaniyets L, Goodman AB, Belay B, Freedman DS, Sucusky MS, Lange SJ, et al. Body mass index and risk for COVID-19–related hospitalization, intensive care unit admission, invasive mechanical ventilation, and death—United States, March–December 2020. *Morbidity and Mortality Weekly Report*. 2021;70(10):355.
8. Guan W-j, Liang W-h, Zhao Y, Liang H-r, Chen Z-s, Li Y-m, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *European Respiratory Journal*. 2020;55(5).
9. Holman N, Knighton P, Kar P, O'Keefe J, Curley M, Weaver A, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. *The lancet Diabetes & endocrinology*. 2020;8(10):823-33.
10. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *International journal of infectious diseases*. 2020;94:91-5.
11. Zhu L, She Z-G, Cheng X, Qin J-J, Zhang X-J, Cai J, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. *Cell metabolism*. 2020;31(6):1068-77. e3.
12. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. *Journal of infection*. 2020;81(2):e16-e25.
13. Pal R, Bhadada SK, Misra A. COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2021;15(2):505-8.
14. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2020;14(4):303-10.
15. Wang W, Chen H, Li Q, Qiu B, Wang J, Sun X, et al. Fasting plasma glucose is an independent predictor for severity of H1N1 pneumonia. *BMC Infectious Diseases*. 2011;11(1):1-6.

16. Butler SO, Btaiche IF, Alaniz C. Relationship between hyperglycemia and infection in critically ill patients. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*. 2005;25(7):963-76.
17. Wurtz R, Cameron BJ. Electronic laboratory reporting for the infectious diseases physician and clinical microbiologist. *Clinical infectious diseases*. 2005;40(11):1638-43.
18. Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. *Diabetes & metabolic syndrome*. 2020 May-Jun;14(3):211-2. PubMed PMID: 32172175. Pubmed Central PMCID: PMC7102582. Epub 2020/03/17. eng.
19. Yan AF, Sun X, Zheng J, Mi B, Zuo H, Ruan G, et al. Perceived risk, behavior changes and Health-related outcomes during COVID-19 pandemic: Findings among adults with and without diabetes in China. *Diabetes research and clinical practice*. 2020 Sep;167:108350. PubMed PMID: 32710996. Pubmed Central PMCID: PMC7375325. Epub 2020/07/28. eng.
20. Al-Ozairi E, Brown R, Hamdan Y, Alabdullah L, Voase N, Al Kandari J, et al. Risk of mortality among inpatients with COVID-19 and type 2 diabetes: National data from Kuwait. *Endocrinology, Diabetes & Metabolism*. 2021;4(4):e00287.
21. <COVID-19 diabetes and death.pdf>.
22. Neves MT, de Matos LV, Vasques AC, Sousa IE, Ferreira I, Peres S, et al. COVID-19 and aging: Identifying measures of severity. *SAGE Open Med*. 2021;9:20503121211027462-. PubMed PMID: 34249362. eng.
23. Leulseged TW, Abebe KG, Hassen IS, Maru EH, Zewde WC, Chamiso NW, et al. COVID-19 disease severity and associated factors among Ethiopian patients: A study of the millennium COVID-19 care center. *PloS one*. 2022;17(1):e0262896.
24. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. *The lancet Diabetes & endocrinology*. 2020 Sep;8(9):782-92. PubMed PMID: 32687793. Pubmed Central PMCID: PMC7367664. Epub 2020/07/21. eng.
25. de Siqueira JVV, Almeida LG, Zica BO, Brum IB, Barceló A, de Siqueira Galil AG. Impact of obesity on hospitalizations and mortality, due to COVID-19: A systematic review. *Obesity research & clinical practice*. 2020 Sep-Oct;14(5):398-403. PubMed PMID: 32736969. Pubmed Central PMCID: PMC7377684. Epub 2020/08/02. eng.

26. Nikniaz Z, Somi MH, Dinevari MF, Taghizadieh A, Mokhtari L. Diabesity Associates with Poor COVID-19 Outcomes among Hospitalized Patients. *Journal of obesity & metabolic syndrome*. 2021 Jun 30;30(2):149-54. PubMed PMID: 33927066. Pubmed Central PMCID: PMC8277582. Epub 2021/05/01. eng.
27. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requiring invasive mechanical ventilation. *Obesity*. 2020;28(7):1195-9.
28. Alwarawrah Y, Kiernan K, MacIver NJ. Changes in nutritional status impact immune cell metabolism and function. *Frontiers in immunology*. 2018;9:1055.
29. Tanaka SI, Isoda F, Ishihara Y, Kimura M, Yamakawa T. T lymphopaenia in relation to body mass index and TNF- α in human obesity: adequate weight reduction can be corrective. *Clinical endocrinology*. 2001;54(3):347-54.
30. Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. *European heart journal*. 2020;41(22):2058-66.
31. Kanwal A, Agarwala A, Martin LW, Handberg E, Yang E. COVID-19 and hypertension: What we know and don't know. *American College of Cardiology*. 2020;6.
32. Mubarik S, Liu X, Eshak ES, Liu K, Liu Q, Wang F, et al. The Association of Hypertension With the Severity of and Mortality From the COVID-19 in the Early Stage of the Epidemic in Wuhan, China: A Multicenter Retrospective Cohort Study. *Frontiers in medicine*. 2021;8:631.
33. Chen J, Liu Y, Qin J, Ruan C, Zeng X, Xu A, et al. Hypertension as an independent risk factor for severity and mortality in patients with COVID-19: a retrospective study. *Postgraduate medical journal*. 2021.
34. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *The lancet respiratory medicine*. 2020;8(4):e21.
35. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. *Virologica Sinica*. 2020;35(3):266-71.

36. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? *Journal of autoimmunity*. 2020;111:102452.
37. Loperena R, Van Beusecum JP, Itani HA, Engel N, Laroumanie F, Xiao L, et al. Hypertension and increased endothelial mechanical stretch promote monocyte differentiation and activation: roles of STAT3, interleukin 6 and hydrogen peroxide. *Cardiovascular research*. 2018;114(11):1547-63.
38. Faghieh Dinevari M, Somi MH, Sadeghi Majd E, Abbasalizad Farhangi M, Nikniaz Z. Anemia predicts poor outcomes of COVID-19 in hospitalized patients: a prospective study in Iran. *BMC infectious diseases*. 2021;21(1):1-7.
39. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *The Lancet Respiratory Medicine*. 2020;8(5):475-81.
40. Cecconi M, Piovani D, Brunetta E, Aghemo A, Greco M, Ciccarelli M, et al. Early predictors of clinical deterioration in a cohort of 239 patients hospitalized for Covid-19 infection in Lombardy, Italy. *Journal of clinical medicine*. 2020;9(5):1548.
41. Cure E, Cure MC. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2020;14(4):349-50.
42. Zahid U, Ramachandran P, Spitalewitz S, Alasadi L, Chakraborti A, Azhar M, et al. Acute kidney injury in COVID-19 patients: an inner city hospital experience and policy implications. *American journal of nephrology*. 2020;51(10):786-96.
43. Paek JH, Kim Y, Park WY, Jin K, Hyun M, Lee JY, et al. Severe acute kidney injury in COVID-19 patients is associated with in-hospital mortality. *PloS one*. 2020;15(12):e0243528.
44. Gabarre P, Dumas G, Dupont T, Darmon M, Azoulay E, Zafrani L. Acute kidney injury in critically ill patients with COVID-19. *Intensive care medicine*. 2020 Jul;46(7):1339-48. PubMed PMID: 32533197. Pubmed Central PMCID: PMC7290076. Epub 2020/06/14. eng.
45. Shao M, Li X, Liu F, Tian T, Luo J, Yang Y. Acute kidney injury is associated with severe infection and fatality in patients with COVID-19: A systematic review and meta-analysis of 40 studies and 24,527 patients. *Pharmacological research*. 2020;161:105107.

46. Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. *The lancet HIV*. 2021 Jan;8(1):e24-e32. PubMed PMID: 33316211. Pubmed Central PMCID: PMC7773630. Epub 2020/12/15. eng.
47. Inciarte A, Gonzalez-Cordon A, Rojas J, Torres B, de Lazzari E, de la Mora L, et al. Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study. *AIDS (London, England)*. 2020 Oct 1;34(12):1775-80. PubMed PMID: 32773471. Pubmed Central PMCID: PMC7493771. Epub 2020/08/11. eng.
48. Parker A, Koegelenberg CFN, Moolla MS, Louw EH, Mowlana A, Nortjé A, et al. High HIV prevalence in an early cohort of hospital admissions with COVID-19 in Cape Town, South Africa. *South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde*. 2020 Aug 21;110(10):982-7. PubMed PMID: 33205724. Epub 2020/11/19. eng.
49. Gervasoni C, Meraviglia P, Riva A, Giacomelli A, Oreni L, Minisci D, et al. Clinical Features and Outcomes of Patients With Human Immunodeficiency Virus With COVID-19. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020 Nov 19;71(16):2276-8. PubMed PMID: 32407467. Pubmed Central PMCID: PMC7239244. Epub 2020/05/15. eng.
50. Qomara WF, Primanissa DN, Amalia SH, Purwadi FV, Zakiyah N. Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review. *International journal of general medicine*. 2021;14:8557-71. PubMed PMID: 34849001. Pubmed Central PMCID: PMC8627269. Epub 2021/12/02. eng.
51. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Bethesda MD2021.